split-banner-image

TEXT

Closed

IBCSG 25-02/BIG 3-02: TEXT

BCT Study Chair:

Prue Francis

A phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer.

international

2423

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

249

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

24

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

TEXT PUBLICATIONS

2024

Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.

Early Breast Cancer Trialists’ Collaborative Group. The Lancet. 2024; 4041407-18, epub 12 October 2024, E-pub

2022

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials.

Pagani* O, Walley* BA, Francis GF, Colleoni M, Láng I, Gomez Hl, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winder EP, Ruepp B, Loi S, Coates AS, Gelber RD, Goldhirsch A, Regan** MM, Francis** PA, for the SOFT and TEXT Investigators and the International Breast Cancer Study Group. *Co-lead authors. **Co-last authors. Journal of Clinical Oncology. 2022; Epub 15 December 2022. doi: 10.1200/JCO.22.01064, E-pub

Back to the Beginning: The role of ovarian suppression in management of hormone sensitive breast cancer in premenopausal women.

Connolly RM, Miller RD. Journal of Clinical Oncology. 2022; epub 15 December 2022 doi: 10.1200/JCO.22.02319., Editorial

Historical early treatment effects of adjuvant endocrine therapy for breast cancer in high-risk subgroups: Reanalysis of BIG 1-98, SOFT and TEXT.

Regan MM, Niman SM, Fleming GF, Walley B, Viale G, Thurlimann BJK, Loi S, Colleoni M, Pagani O, Francis PA. Journal of Clinical Oncology. 2022; 40(16 suppl):ASCO Abstract #508, Abstract

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.

Bradley R, Braybrooke J, Gray R, Hills R, Liu Z, Pan H, Peto R, Dodwell D, McGale P, Taylor C, Bergh J, Swain S, Francis PA, Gnant M, Perrone F, Regan MM, for the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Lancet Oncology. 2022; 23(3):382-392, epub 03 February 2022, E-pub

2021

Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials.

Regan MM, Walley BA, Fleming GF, Francis PA, Colleoni MA, Lang I, Gomez HL, Tondini CA, Burstein HJ, Goetz MP, Ciruelos EM, Stearns VJ, Bonnefoi HR, Martino S, Geher Jr CE, Chini C, Minisini AM, Spazzapan S, Fuhstaller T, Winer EP, Ruepp B, Loi S, Coates AS, Goldhirsch A, Gelber RD, Pagani O. SABCS 2021; GS2-05, Abstract

LOAD MORE

Institutions